Zimmerman Christina
Changes in Health Care Financing & Organization (HCFO), USA.
Find Brief. 2012 Nov;15(8):1-3.
Key findings. (1) Zero copayment for generic drugs is the greatest influencer of generic statin utilization. (2) Both higher copayments for generic drugs and lower copayments for competing brands are associated with a decreased probability of using generic statins. (3) Prior authorization and step therapy requirements for brand-name statins are associated with an increased use of generic drugs. (4) Greater use of generic statins should reduce costs for patients, plans, and Medicare.
主要发现。（1）仿制药零自付费用是仿制药他汀类药物使用的最大影响因素。（2）仿制药较高的自付费用和竞争品牌较低的自付费用都与使用仿制药他汀类药物的可能性降低有关。（3）品牌他汀类药物的预先授权和逐步治疗要求与仿制药使用增加有关。（4）更多地使用仿制药他汀类药物应能降低患者、保险计划和医疗保险的成本。
